Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Sotagliflozin Commercial vs Development Formulations
NCT03211195Phase 1Completed
- Sponsor
- Sanofi
- Start
- Jun 2017
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sotagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Sanofi. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve to Last Quantifiable Concentration and 1 more. Started Jun 2017; status: completed.
02
Drugs
sotagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03211195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03211195.